Search results
Results from the WOW.Com Content Network
Amblyopia. Anisometropia is a condition in which a person's eyes have substantially differing refractive power. [ 1] Generally, a difference in power of one diopter (1D) is the threshold for diagnosis of the condition. [ 2][ 3] Patients may have up to 3D of anisometropia before the condition becomes clinically significant due to headache, eye ...
It was granted a rare pediatric disease designation for the treatment of pediatric NF-1 along with a rare pediatric disease priority review voucher. [14] In April 2020, selumetinib was approved by the FDA for the treatment of children with NF-1. [21] [22] [15] It is the first drug approved in the US to treat this rare disease. [14]
August 14, 2024 at 3:32 PM. A team of divers looking for a woman and her young daughter who vanished in 1974 located their car and likely human remains in a Florida canal, authorities said this ...
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
Earlier this year, the U.S. Department of Health and Human Services announced plans to fight the syphilis epidemic, which included addressing drug shortages, enhancing community input through ...
02:45. Semaglutide for weight loss has been in shortage since 2022, according to the FDA’s drug shortage database. Tirzepatide, which was approved for weight loss in the U.S. only in November ...
Serotonin–norepinephrine reuptake inhibitors ( SNRIs) are a class of antidepressant medications used to treat major depressive disorder (MDD), anxiety disorders, social phobia, chronic neuropathic pain, fibromyalgia syndrome (FMS), and menopausal symptoms. Off-label uses include treatments for attention-deficit hyperactivity disorder (ADHD ...
August 9, 2024 at 5:27 PM. WASHINGTON (AP) — Federal health regulators on Friday declined to approve the psychedelic drug MDMA as a therapy for PTSD, a major setback for groups seeking a ...